Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

(2011) K. Ahn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor

(2010) Douglas S. Johnson et al.   ACS Medicinal Chemistry Letters

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

(2009) Kay Ahn et al.   Expert Opinion on Drug Discovery

Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization

(2009) Joe Palandra et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System

(2008) Kay Ahn et al.   CHEMICAL REVIEWS

The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors

(2008) Barbara Costa et al.   PAIN

Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms

(2006) Leon Chang et al.   BRITISH JOURNAL OF PHARMACOLOGY